126 related articles for article (PubMed ID: 7625812)
1. In vitro activity of rokitamycin, a new macrolide, against Borrelia burgdorferi.
Cinco M; Padovan D; Stinco G; Trevisan G
Antimicrob Agents Chemother; 1995 May; 39(5):1185-6. PubMed ID: 7625812
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.
Dever LL; Jorgensen JH; Barbour AG
Antimicrob Agents Chemother; 1993 Aug; 37(8):1704-6. PubMed ID: 8215288
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.
Sicklinger M; Wienecke R; Neubert U
J Clin Microbiol; 2003 Apr; 41(4):1791-3. PubMed ID: 12682190
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the degree of susceptibility of Streptococcus pyogenes erythromycin-resistant strains to rokitamycin (a 16-membered macrolide) using the Epsilometer test.
Crotti D; Rossetti R; Braga PC
Drugs Exp Clin Res; 2004; 30(1):17-26. PubMed ID: 15134387
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory and bactericidal activity of rokitamycin against Helicobacter pylori and morphological alterations.
Brenciaglia MI; Fornara AM; Scaltrito MM; Braga PC
J Chemother; 1996 Dec; 8(6):425-31. PubMed ID: 8981182
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activity of rokitamycin compared with that of other macrolides.
Yu KW; Briones F; Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(4):331-5. PubMed ID: 1889182
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of YM133, a new semisynthesized macrolide.
Terasawa T; Watanabe M; Okubo T; Mitsuhashi S
Antimicrob Agents Chemother; 1991 Jul; 35(7):1370-5. PubMed ID: 1929295
[TBL] [Abstract][Full Text] [Related]
8. The post-antibiotic effects of rokitamycin (a 16-membered ring macrolide) on susceptible and erythromycin-resistant strains of Streptococcus pyogenes.
Braga PC; Culici M; Dal Sasso M
Int J Antimicrob Agents; 2004 Sep; 24(3):254-60. PubMed ID: 15325429
[TBL] [Abstract][Full Text] [Related]
9. Three species of Borrelia burgdorferi sensu lato (B. burgdorferi sensu stricto, B afzelii, and B. garinii) identified from cerebrospinal fluid isolates by pulsed-field gel electrophoresis and PCR.
Busch U; Hizo-Teufel C; Boehmer R; Fingerle V; Nitschko H; Wilske B; Preac-Mursic V
J Clin Microbiol; 1996 May; 34(5):1072-8. PubMed ID: 8727878
[TBL] [Abstract][Full Text] [Related]
10. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates.
Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V
Int J Antimicrob Agents; 2000 Jun; 15(1):11-7. PubMed ID: 10856671
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of antimicrobial and bactericidal activities and postantibiotic effects of macrolides antibiotics against clinical isolates, and examination of shape alteration by scanning electron microscope].
Yano H; Kobayashi T; Okitsu N; Aoki A; Toriya M; Nakada Y; Sagai H; Iyobe S; Inoue M
Jpn J Antibiot; 2007 Feb; 60(1):31-46. PubMed ID: 17436861
[TBL] [Abstract][Full Text] [Related]
12. [Borrelia burgdorferi Group: in-vitro antibiotic sensitivity].
Henneberg JP; Neubert U
Orv Hetil; 2002 May; 143(21):1195-8. PubMed ID: 12073540
[TBL] [Abstract][Full Text] [Related]
13. In vitro assessment of rokitamycin against problem gram-positive cocci.
Hamilton-Miller JM; Maple PA
J Chemother; 1992 Feb; 4(1):6-8. PubMed ID: 1403073
[TBL] [Abstract][Full Text] [Related]
14. Rokitamycin: bacterial resistance to a 16-membered ring macrolide differs from that to 14- and 15-membered ring macrolides.
Braga PC
J Chemother; 2002 Apr; 14(2):115-31. PubMed ID: 12017366
[TBL] [Abstract][Full Text] [Related]
15. Effects of rokitamycin and other macrolide antibiotics on Mycoplasma pneumoniae in L cells.
Misu T; Arai S; Furukawa M; Yamamoto Y; Miyazaki T
Antimicrob Agents Chemother; 1987 Nov; 31(11):1843-5. PubMed ID: 3124740
[TBL] [Abstract][Full Text] [Related]
16. [Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].
Okubo T; Iyobe S; Fujiki Y; Sagai H
Jpn J Antibiot; 2003 Jun; 56(3):163-70. PubMed ID: 12942787
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.
Baradaran-Dilmaghani R; Stanek G
Infection; 1996; 24(1):60-3. PubMed ID: 8852472
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of BmpA (P39) among European isolates of Borrelia burgdorferi sensu lato and influence of interspecies variability on serodiagnosis.
Roessler D; Hauser U; Wilske B
J Clin Microbiol; 1997 Nov; 35(11):2752-8. PubMed ID: 9350727
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species.
Yazawa K; Mikami Y; Sakamoto T; Ueno Y; Morisaki N; Iwasaki S; Furihata K
Antimicrob Agents Chemother; 1994 Sep; 38(9):2197-9. PubMed ID: 7811046
[TBL] [Abstract][Full Text] [Related]
20. Dialysis culture for determination of MIC and MBC of benzylpenicillin against Borrelia burgdorferi.
Stiernstedt SH; Tadesse T; Wretlind B
APMIS; 1999 Apr; 107(4):380-2. PubMed ID: 10230690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
